Green tea polyphenol (epigallocatechin-3-gallate) improves gut dysbiosis and serum bile acids dysregulation in high-fat diet-fed mice.

Gut microbiota have profound effects on bile acid metabolism by promoting deconjugation, dehydrogenation, and dehydroxylation of primary bile acids in the distal small intestine and colon. High-fat diet-induced dysbiosis of gut microbiota and bile acid dysregulation may be involved in the pathology of steatosis in patients with non-alcoholic fatty liver disease. Epigallocatechin-3-gallate (EGCG), the most abundant polyphenolic catechin in green tea, has been widely investigated for its inhibitory or preventive effects against fatty liver. The aim of the present study was to investigate the effects of EGCG on the abundance of gut microbiota and the composition of serum bile acids in high-fat diet-fed mice and determine the specific bacterial genera that can improve the serum bile acid dysregulation associated with EGCG anti-hepatic steatosis action. Male C57BL/6N mice were fed with the control diet, high-fat diet, or high-fat diet + EGCG at a concentration of 0.32% for 8 weeks. EGCG significantly inhibited the increases in weight, the area of fatty lesions, and the triglyceride content in the liver induced by the high-fat diet. Principal coordinate analysis revealed significant differences in microbial structure among the groups. At the genus level, EGCG induced changes in the microbiota composition in high-fat diet-fed mice, showing a significantly higher abundance of

Déclaration de conflit d'intérêts

YN received scholarship funding from EA Pharma Co., Ltd. and collaboration research funding from Fujifilm Medical Co., Ltd. and has been paid lecture fees by Janssen Pharma K.K., Mylan EPD Co., Takeda Pharma. Co., Ltd., Mochida Pharma. Co., Ltd., EA Pharma Co., Ltd., Otsuka Pharma. Co., Ltd., Astellas Pharma Inc. and Miyarisan Pharma. Co., Ltd. ZY and TO are having the limited stock ownership as an employee of the company. No further financial interest is stated. The research was partly funded by these funds. Neither the funding agency nor any outside organization has participated in study design or have any competing of interest. These pharmaceutical companies had final approval of the manuscript. YI has an affiliation with a donation-funded department from Nichinichi Pharmaceutical Co., Ltd. The other authors have no conflicts of interest to disclose.